TrialJournal of Crohn's & colitis2025

Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study.

Severine Vermeire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.